Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 12, 2011

ExcellGene Extends Supply Agreement for Polyplus-Transfection's Reagents

  • ExcellGene, a provider of solutions for protein manufacturing and process development based on mammalian cells, has signed an extended supply agreement for polyethylenimine (PEI)-based transfection reagents produced by Polyplus-transfection.

    The company will supply ExcellGene with batches of linear PEI transfection reagents that are designed to ensure reliable, safe, and reproducible protein production in the medium-to-large scale ranges. By purchasing PEI from Polyplus-transfection, ExcellGene benefits from Polyplus’ intellectual property rights for the use of PEI in transient and stable transfection. Polyplus-transfection supplies its reagents for the transfection of genes, oligonucleotides, and siRNA.

    ExcellGene says that it has attracted more than 100 international clients. The firm's offerings cover vectors, gene transfer systems, cell hosts, screening platforms for cells and processes, scale-up principles, and bioreactors. Last year, the company won approval from the Swiss regulatory agency for production of APIs at its cGMP manufacturing facility, which features bioreactors of up to 250 L.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »